Search Results - "Hagins, D."

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials by Hagins, D, Orkin, C, Daar, ES, Mills, A, Brinson, C, DeJesus, E, Post, FA, Morales‐Ramirez, J, Thompson, M, Osiyemi, O, Rashbaum, B, Stellbrink, H‐J, Martorell, C, Liu, H, Liu, Y‐P, Porter, D, Collins, SE, SenGupta, D, Das, M

“…Objectives The single‐tablet regimen rilpivirine, emtricitabine and tenofovir alafenamide (RPV/FTC/TAF) for treatment of HIV‐1‐infected adults was approved…”
Get full text

Improved solid-phase synthesis of α,α-dialkylated amino acid-rich peptides with antimicrobial activity by Haynes, S.R., Hagins, S.D., Juban, M.M., Elzer, P.H., Hammer, R.P.

“…:  A homologous series of nonapeptides and their acetylated versions were successfully prepared using solid‐phase synthetic techniques. Each nonapeptide was…”
Get full text

A comparison of the N-terminal amino acid sequences of early and late pools of anti-DNP and anti-DNP-p-aminobenzoylglutamate antibody light chains by Hagins, D M, Bray, V H, Henke, J, Lovins, R E

“…The N-terminal amino acid sequences of early and late pools of anti-DNP and anti-DNP-p-aminobenzoylglutamate (DNP-ABG) antibody light chains were…”
Get full text

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study by Cahn, Pedro, Dr, Pozniak, Anton L, MD, Mingrone, Horacio, MD, Shuldyakov, Andrey, MD, Brites, Carlos, MD, Andrade-Villanueva, Jaime F, MD, Richmond, Gary, MD, Buendia, Carlos Beltran, MD, Fourie, Jan, MD, Ramgopal, Moti, MD, Hagins, Debbie, MD, Felizarta, Franco, MD, Madruga, Jose, MD, Reuter, Tania, MD, Newman, Tamara, MD, Small, Catherine B, MD, Lombaard, John, MD, Grinsztejn, Beatriz, MD, Dorey, David, MMath, Underwood, Mark, PhD, Griffith, Sandy, PharmD, Min, Sherene, MD

“…Summary Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We…”
Get full text

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study by Squires, Kathleen, MD, Kityo, Cissy, MSc, Hodder, Sally, Prof, Johnson, Margaret, FRCP, Voronin, Evgeny, MD, Hagins, Debbie, MD, Avihingsanon, Anchalee, Koenig, Ellen, Jiang, Shuping, PhD, White, Kirsten, PhD, Cheng, Andrew, MD, Szwarcberg, Javier, MD, Cao, Huyen, Dr

“…Summary Background Women are under-represented in HIV antiretroviral therapy (ART) studies. Guidelines for selection of ART as initial therapy in patients with…”
Get full text